Adenocarcinoma In Situ — Trials

Adenocarcinoma In Situ — Trials · CancerIndex

Clinical trials

Registered studies

210 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 61
Recruiting: 31
Ph III recruiting: 3
Growth YoY: —
Industry share: 5%
Top sponsor: National Cancer Institute (NCI)
Termination share: 34.2%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (32)

clinicaltrialsPublishedShowing 1–7 of 7 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT02750826	Breast Cancer WEight Loss Study (BWEL Study)	active not recruiting	Phase 3	3,177	Alliance for Clinical Trials in OncologyOTHER	4	Sep 2, 2026	clinicaltrials
NCT02954874	Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer	active not recruiting	Phase 3	1,195	National Cancer Institute (NCI)NIH	3	Aug 31, 2026	clinicaltrials